MTOR and lung cancer: Alterations in different components of the PI3K/Akt/mTOR pathway, including somatic mutations of PIK3CA, deletions of PTEN, and increased Akt activity, have been recorded in most NSCLC cases, resulting in this pathway being one of the most frequently deregulated in lung cancer [107,108,109].